Last reviewed · How we verify

NCT04472442

Intermittent Hypoxia Paired with High Intensity Training in Brain Injury

Completed NA Last updated 17 October 2024
What this trial tests

NA trial testing Intermittent hypoxia in Brain Injuries in 35 participants. Completed in 30 June 2023.

Timeline
1 August 2020
Primary endpoint
30 June 2023
30 June 2023

Quick facts

Lead sponsorIndiana University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment35
Start date1 August 2020
Primary completion30 June 2023
Estimated completion30 June 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Indiana University

Who can join

Adults 18 to 85, any sex, with Brain Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The central hypotheses are that HIT combined with AIH results in: 1) greater locomotor gains as compared to HIT alone; 2) improvements in gait quality and motor coordination during walking, and 3) changes in measures of community participation and integration.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Acute Intermittent Hypoxia With High-Intensity Gait Training in Chronic Stroke: A Phase II Randomized Crossover Trial.
    Hornby TG, Plawecki A, Lotter JK, Shoger LH, et al · · 2024 · cited 8× · PMID 38860389 · DOI 10.1161/strokeaha.124.047261

Verify or expand the search:

Other trials of Intermittent hypoxia

Trials testing the same drug.

Other recruiting trials for Brain Injuries

Currently open trials in the same condition.

Other Indiana University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04472442.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing